As of Wednesday close, Seres Therapeutics Inc.’s (NASDAQ:MCRB) stock was up $0.42, moving up 6.33 percent to $7.06. The average number of shares traded per day over the past five days has been 463,140 shares. 3 times new highs have been achieved over the past 5 days, with a $0.21 gain in that time frame. In the last twenty days, the average volume was 951,235, while in the previous 50 days, it was 1,010,320.
Since last month, MCRB stock rose 22.36%. Shares of the company fell to $5.66 on 10/24/22, the lowest level in the past month. A 52-week high of $11.69 was reached on 11/01/22 after having rallying from a 52-week low of $2.50. Since the beginning of this year, MCRB’s stock price has dropped by -15.25% or -$1.27, and marked a new high 4 times. However, the stock has declined by -39.61% since its 52-week high.
China Can't Stop US$0.25 Stock from Mining Ultra-Rare Metal
Here's one little-known company — trading undiscovered below 25-cents per share — that's advancing one of the largest and highest quality REE deposits in all of North America... and the Chinese can't do a damn thing about it! It's early stage... and that's excellent news for individual investors like you who have the foresight to act decisively on an emerging megatrend that's already being measured in the Tens of $Billions.
Simply click here and the name & trading symbol are yours.
MCRB stock investors should be aware that Seres Therapeutics Inc. (MCRB) stock had its last reported insider trading activity 24 days ago on Oct 31. Ege David S., the of the company, disposed of 5,012 shares for $7.93 on Oct 31. It resulted in a $39,745 divestment by the insider. Nutritional Health LTP Fund Ge added 8,738,243 shares at an average price of $3.15 on Jul 05. The insider now owns 5,875,711 shares following the transaction.
The stock’s beta is 2.78. Besides these, the trailing price-to-sales (P/S) ratio of 64.49, the price-to-book (PB) ratio of 12.84.
In the three months ended June 29, Seres Therapeutics Inc.’s quick ratio stood at 3.00, while its current ratio was 3.00, showing that the company is able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending June 29 was 0.75. Based on annual data, MCRB earned $209.42 million in gross profit and brought in $144.93 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -41.30%. Return on equity (ROE) for the past 12 months was -305.30%.
In Seres Therapeutics Inc.’s quarter-end financial report for June 29, it reported total debt of $50.86 million against cash and short-term investments of $27.61 million. According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. MCRB’s revenue fell -3584.01% to $1.22 million during the quarter, while net income inched up to $3.44 million. While analysts expected Seres Therapeutics Inc. to report -$0.6 quarterly earnings, the actual figure was -$0.7 per share, beating the consensus estimate by -16.70%. During the quarter, the company generated -$57.01 million in EBITDA. The liabilities of Seres Therapeutics Inc. were 244.28 million at the end of its most recent quarter ended June 29, and its total debt was $77.21 million. The value of shareholders’ equity is $124.59 million.
This quick technical analysis looks at Seres Therapeutics Inc.’s (MCRB) price momentum. With a historical volatility rate of 54.07%, the RSI 9-day stood at 49.49% on 23 November.
With respect to its five-day moving average, the current Seres Therapeutics Inc. price is up by +3.07% percent or $0.21. At present, MCRB shares trade +7.13% above its 20-day simple moving average and +84.33% percent above its 100-day simple moving average. However, the stock is currently trading approximately -1.94% below its SMA50 and -4.85% below its SMA200.
Stochastic coefficient K was 14.47% and Stochastic coefficient D was 9.06%, while ATR was 0.52. Given the Stochastic reading of 28.67% for the 14-day period, the RSI (14) reading has been calculated as 49.80%. As of today, the MACD Oscillator reading stands at -0.15, while the 14-day reading stands at -0.43.
Seres Therapeutics Inc. downgraded its rating on Seres Therapeutics Inc. (NASDAQ: MCRB) to a Sell in a note to investors on July 23, 2021. The analysts firm previously had a Neutral rating on the stock.Seres Therapeutics Inc. (MCRB) has been rated Overweight by analysts. According to 1 brokerage firm, MCRB is a sell, and 0 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Seres Therapeutics Inc. stock as buy, with 7 recommending it as overweight.
With a median target price of $12.00, the current consensus forecast for the stock is $4.00 – $25.00. Based on these forecasts, analysts predict Seres Therapeutics Inc. (MCRB) will achieve an average price target of $12.86.